Shingrix Approved to Prevent Shingles in Immunocompromised Adults
Previously, the vaccine was only approved for adults 50 years of age and older.
Previously, the vaccine was only approved for adults 50 years of age and older.
Despite the availability of a highly effective shingles vaccine and almost universal risk among those born before 1980, Americans are not getting vaccinated.
Review of the Advisory Committee Immunization Practices updates to the pediatric immunization schedule and significant revisions to the adult immunization schedule.
From 2008 to 2018, there was an increase in shingles vaccination among adults aged 60 years, with variations in vaccination rates.
A modest but long-lasting protective effect was observed, but full protection not achieved.
A patient presents to the emergency department complaining of headache behind her left eye and redness of the left eyelid.
Researchers sought to compare the effectiveness and cost-savings of the recombinant subunit zoster vaccine with that of the live attenuated zoster vaccine in individuals aged ≥50 years.
Highest rates of HZO seen in older adults, women, and in whites vs other racial groups.
Total of 4381 reports of adverse events during first 8 months of use; 3% were serious.
However, adjuvant recombinant subunit vaccine tied to more injection site adverse events.